Heat shock protein 90 (hsp90) is associated with many steroid receptors in tissue homogenates. It is widely accepted that hsp90 regulates the binding of the receptor to the corresponding gene regulatory element. However there is no unequivocal evidence that steroid receptor-hsp90 complexes are present in the intact cells. We demonstrate here the absence of progesterone receptor (PR)-hsp90 complexes in intact target cell nuclei, using immunohistochemical and biochemical methods to determine the location and composition of the nonliganded (aporeceptor) and liganded (holoreceptor) PR complexes. In the chicken oviduct ceUls, both apo-and holoreceptors were nuclear, while hsp90 was exdusively cytoplasmic.
When expressed transiently in HeLa cels, hsp90 was detected in the cytoplasm and PR was detected in the nucleus. Their location or staining intensity was not affected when they were coexpressed in the same cells. To confirm that the sensitivity of the immunohistochemical detection of hsp90 and PR did not differ siguificantly, a chimeric hsp90-PR was transiently expressed in HeLa cells. Both hsp90 and PR antigens of the chimera were detected in nuclei with the same intensity. In homogenates of the same tissue samples that were used for immunohistochemistry, the PR was complexed with hsp90. Hsp9O-PR complexes were formed in vitro when immature bursa of Fabricius, known to contain high levels of hsp90, was homogenized in the presence of hsp90-free aporeceptor, while holoreceptor did not associate with hsp90. Our data show that nuclear PR is not complexed with hsp90 in vivo and suggest that the 8S-PR may be an in vitro artifact generated during tissue procesing.
Steroid receptors are transcription factors that regulate gene expression upon binding of their cognate ligands (1) (2) (3) (4) (5) . The mechanism by which the ligand regulates their activity is not known. Ligand binding may induce changes in receptor structure to allow DNA binding, dimerization, and interaction with other transcription factors or cause a dissociation of an inhibiting factor. Evidence for the latter effect came from a large number of in vitro studies. Steroid receptors were found to be in hypotonic cell lysate in a non-DNA-binding form (sedimenting at 8 S in sucrose gradient), which is an oligomeric complex of steroid receptor and heat shock protein 90 (hsp90). Hypertonic conditions or heating triggers dissociation of the hsp90 from the complex and transformation of the receptor to a DNA-binding form (4S) (6, 7) . Since the complex between steroid receptors and the hsp90 is less stable in the presence of hormone, it has been proposed that hormone binding might trigger the dissociation also in vivo and thus result in an active receptor (8) .
There are a vast number of studies on in vitro transformation of steroid receptors from the non-DNA-binding form to the DNA-binding form (6) . There are also many studies on the The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 (9) (10) (11) (12) (13) (14) , whereas hsp90 is, according to most studies, located in the cytoplasm (14) (15) (16) Immunohistochemistry. The samples were frozen in liquid nitrogen, dried in vacuum, and processed for immunohistochemistry (13) . Fixation with p-benzoquinone or formaldehyde vapor gave essentially similar results. Polyclonal antibody IgGRB (17) ; monoclonal antibodies PR6, PR13, and PR22 (18) against affinity-purified PR; and monoclonal antibodies BF4, 7Da, and 4F3 against hsp90 (19, 20) Cytosols and Nuclear Extracts. These were prepared as described (10, 11) . Equal aliquots of the cytosol and nuclear extracts were taken so that the final PR concentrations were comparable and quantitative. Some samples of KCl-treated cytosols were dialyzed and thereafter homogenized 1:1 (vol/ vol) with bursa of Fabricius of immature chicken (not treated with estradiol), after which molybdate was added.
Recombinants. chsp90 cDNA was subcloned into the eukaryotic expression vector pSG5 (21) . To make NLS-hsp90, a cDNA sequence corresponding to the nuclear localization signal (NLS) of human ER (amino acids 253-303) was amplified by PCR and ligated in front of the coding sequence of chsp90 in pSG5 (22) . A fusion protein between chsp90 and cPR (cPR-HSP2) was constructed by amplifying 990 N-terminal nucleotides of chsp90 cDNA by PCR and ligating into the Xho I site of cPR21, which is a pSG5 expression vector containing the whole cPR coding region. The Xho I site is located immediately before the first ATG (23) .
Transfections and Immunohistochemical Analysis of Transfected Cells. The cDNAs were transiently expressed in HeLa cells by using a standard calcium phosphate precipitation technique (22) . Immunohistochemistry of formalin-fixed cells was studied with the ABC method (22) . Location scoring (22) was done blind by two investigators. Immunoblotting was carried out with a standard technique using antibodies PR22 and 7Da at a concentration of 1 ,g/ml.
Sucrose Gradient Ultracentrifugation. A sucrose gradient (5-20%) was prepared in 10 mM Tris/12 mM monothioglycerol/1.5 mM EDTA/10% (vol/vol) glycerol/50 mM sodium molybdate/0.15 M KCl, pH 7.4. The tubes were centrifuged at 200,000 x g for 16 hr. Fractions (two drops) were collected by piercing the bottom of the tube. Glucose oxidase (7.9 S) sedimenting at 2.0 ml and horseradish peroxidase (3.6 S) sedimenting at 2.9 ml were used as internal standards.
PR Assays (IEMA and DCC). Samples of cytosols and nuclear extracts were assayed by sandwich immunoenzymometric assays (IEMAs) (24) specific for cPR complexes. In brief, the microtiter plates (Nunc) were coated with monoclonal antibody PR6. Samples were incubated overnight at 4°C. The second biotinylated antibody, PR22 (PR-IEMA) or 7Da (PR-hsp90 complex IEMA), and peroxidase-labeled avidin were added. During all incubations, 20 both receptor-free and receptor-bound chsp90 (19, 20, 25) . Staining of chsp90 was specific, since no staining was seen when the antibody was replaced by either buffer or nonspecific antibodies or when the specific antibodies were presaturated with an excess of affinity-purified chsp90 (Fig. 1D) (13) . Only nuclear staining was detected in chicken oviduct tissue sections stained with different anti-PR monoclonal antibodies (Fig. 1C) . The subcellular distribution of the cPR was not affected by progesterone administration. These findings confirm earlier studies that used a different methodological approach (10) (11) (12) (13) (14) . In contrast, three different monoclonal antibodies against chsp90 stained the cytoplasmic compartment (Fig. 1A) . Furthermore, chsp90 transiently expressed in HeLa cells was located in the cytoplasm ( Fig. 2A and Table 1 ), whereas cPR was nuclear; coexpression of chsp90 and cPR did not affect their locations (Table 1) . No change in the location of chsp90 was observed after progesterone exposure for 1 hr (Fig. 1B and Table 1 (Fig. 2 C and D) . When the antibody concentration was decreased to 25 ng/ml, the staining intensity was equally reduced with both antibodies. An equal decrease in the staining intensity was observed when 20 .g instead of 100 ,ug of peroxidase substrate per ml was used. Both the cPR and the chsp90 epitopes were undetectable when the antibody concentration was <25 ng/ml or the substrate concentration was <5 &g/ml. Immunoblot experiments with cytosolic extracts of the transfected HeLa cells revealed a protein of expected size as detected by PR22 and 7Da (Fig. 3) . Moreover, the signals obtained with the two antibodies were very similar when identical aliquots of the same cytosolic extract were used (Fig. 3) . The immunodetection of hsp9O is independent of its intracellular location (Fig. 2 A and B) . Fulllength chsp9O (without nuclear localization signal) can be detected in the cytoplasm ( Fig. 2A) as well as in the nuclei, when chsp9O contains the NLS of ER (Fig. 2B) (Fig. 4A) . However, when the cytosol was prepared without molybdate and in the presence of 0.3 M KCl, the cPR sedimented at 4 S and was not shifted by chsp90 antibodies (Fig. 4 A and B) , indicating that cPR was not complexed with chsp90. When cPR was extracted from highly purified nuclei of oviductal cells of chickens that had not received progesterone, only about 1% of cPR (38 ± 1 fmol/ml with PR6-PR22 IEMA) was recovered. Progesterone treatment increased clearly the amount of the nuclear cPR (169 ± 8 fmol/ml with PR6-PR22 IEMA); however, the major part of cPR remained cytosolic (2044 fmol/ml). Progesterone treatment of the chickens decreased cPR-chsp9O complexes in cytosol from 3795 ± 308 fmol/ml (PR6-7Da IEMA) to 506 ± 63 fmol/ml in 1 hr. The IEMA with PR6 and 7Da showed that no chsp90-cPR complexes were present in the nuclear extracts even when receptors were extracted with molybdate, which is known to stabilize the hsp90-PR complex (6 known to contain high amounts of chsp90 but no detectable cPR (11), the cPR was found to form a complex with the chsp90 (Fig. 4D) .
Ligand Prevents PR-hsp9O Complex Formation. The formation of the chsp90-cPR complexes seems to require nonliganded apoPR (since no 8S PR was observed with liganded holoPR or with apoPR labeled in vitro) when it was thereafter homogenized with bursa (Fig. SB) . Because the nonliganded cPR can reassociate with chsp90 during homogenization (Fig.  4C) , the ligand apparently prevents the complex formation. Indeed, when the animals were administered progesterone in vivo and tissue extract was prepared 1 hr later, cPR (termed holoPR) in the resulting cytosol was considerably less associated with chsp90 (Fig. 5A) . Only the minor 8S cPR peak was shifted by chsp90 antibodies. Because the ligand prevented 8S formation in vitro, it can be reasoned that progesterone administration in vivo more likely prevents the formation of the cPR-chsp90 complex during tissue processing than causes a dissociation of a putative preexisting 8S complex.
DISCUSSION
Since the PR is intranuclear, hsp9O must also be nuclear if it directly interferes with the gene regulatory functions of PR in vivo. However, hsp9O appears to be located mainly in the cytoplasm (14-16), although both cytoplasmic and nuclear location has been reported in rabbit uterine cells (26) . The reason for these conflicting results is unknown. A possible explanation may be that in the latter study liquid fixation was used, which may result in the diffusion of antigens (27, 28) . Here, we have used freeze-dry and vapor-fixation techniques and thus minimized diffusion artifacts. This method clearly shows that hsp9O and PR are located in the chicken different subceliular compartments. Moreover, the sensitivity of the immunological detection of chsp9O and cPR by antibodies 7Da and PR22, respectively, was determined to be equivalent by staining of a chsp9O-cPR chimera expressing both epitopes. Therefore, the amount of intranuclear chsp9O that is supposed to be present in a ratio of 2:1 in a complex with the PR (29) should have been easily detected, if it had been present.
When unliganded PR was analyzed in chicken tissue homogenates, nearly all of the PR was associated with hsp9O, whereas after progesterone treatment in vivo, most of the PR was free ofhsp9O. This has been regarded as evidence that the ligand induces dissociation of hsp9O from receptors (8, (30) (31) (32) lysate as a source for hsp90 (33) (34) (35) . Taken together, the histochemical and biochemical results suggest that PR released from the nucleus during tissue fractionation associates with cytoplasmic hsp90 and that this association is affected by the ligand. Thus, ligand (agonist) binding appears to result in a change in receptor structure and may generate a receptor with a lower affinity for hsp90. It has been proposed that antagonists prevent this conformational change and stabilize the hsp90-receptor complex. The ability of the antihormone RU486 in stabilizing the hsp90-PR complex and thus inhibiting receptor-DNA interaction has been used to explain its antihormone action (36) . However, it has been shown recently that the PR-RU486 complex can bind to its DNA responsive element and can activate both in vivo and in vitro transcription from some promoters (37, 38) . Our results bring into question the proposed role of hsp90 in the activity of PR and, possibly, other steroid receptors. Due to its cytoplasmic compartmentalization, hsp90 cannot be in a complex with PR in the nucleus and thus act as a direct inhibitor of PR functions by, for example, interfering with DNA binding or transcription activation. Indeed, it has been shown recently that steroid hormone receptors do not act as constitutive activators of transcription in nearly hsp90-free yeast cells (39) . hsp90 was found to only affect, for unknown reasons, the sensitivity of the hormonal response (39) . Our data do not exclude that hsp90 may have a role in posttranslational modification or chaperoning (40) of newly synthesized receptor in the cytoplasm, which would be in agreement with the findings in the yeast cell model (39) . At present, it is not clear whether the glucocorticoid receptor (GR), which seems to be at least partially cytoplasmic in the absence of ligand (41) , forms hsp90-GR complexes with distinct biological fuinctions.
